Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oasmia Pharmaceutical and Orion have jointly decided to terminate Paclical Nordic region distribution agreement.
Subscribe to our email newsletter
Following the termination, the Nordic region’s distribution rights will again go back to Oasmia Pharma.
Oasmia Pharma has developed a water soluble formulation of Paclitaxel with the retinoid based platform XR-17.
Paclical, currently in clinical Phase III, is indicated for ovarian cancer.
Other possible indications are non-small cellular lung (NSCL) cancer and malignant melanoma.
Oasmia Pharma is a developer of the next generation cancer drugs based on nanotechnology for human and veterinary use.